Literature DB >> 6289947

Common epithelial tumors of borderline malignancy (carcinomas of low malignant potential).

R E Scully.   

Abstract

The creation of the category of ovarian borderline tumors has been a step forward in classification because it has segregated from the general group of common epithelial cancers a subgroup with an unusually good prognosis. Of all borderline tumors, the serous variety is the least difficult for the pathologist to diagnose. The mucinous borderline tumor is not as easy to recognize when an absence of invasion is used as the sole diagnostic criterion, but evaluation of other architectural as well as cytological features is helpful in making the diagnosis. Although the treatment of the majority of serous and mucinous borderline tumors is well standardized, therapy of residual serous borderline tumor is highly controversial and the treatment for pseudomyxoma peritonei, unsatisfactory. Borderline tumors exist in the endometrioid, clear cell, Brenner, and mixed common epithelial categories, but these tumors have been too rare to date in order to clearly characterize their clinical and pathological features. It is hoped that more can be learned about this general group of tumors by a more widespread recognition of their distinctive clinico-pathologic features and by their acceptance as a special subgroup of ovarian cancer. Their behavior differs strikingly from that of other types of malignant ovarian tumors and it is clear that their management should differ accordingly.

Entities:  

Mesh:

Year:  1982        PMID: 6289947

Source DB:  PubMed          Journal:  Bull Cancer        ISSN: 0007-4551            Impact factor:   1.276


  4 in total

1.  Aberrant promoter methylation of the RASSF1A and APC genes in epithelial ovarian carcinoma development.

Authors:  Rahul Bhagat; Shilpa Chadaga; C S Premalata; G Ramesh; C Ramesh; V R Pallavi; Lakshmi Krishnamoorthy
Journal:  Cell Oncol (Dordr)       Date:  2012-10-10       Impact factor: 6.730

2.  Borderline ovarian tumours in Vaud, Switzerland: incidence, survival and second neoplasms.

Authors:  F Levi; C La Vecchia; L Randimbison; V C Te
Journal:  Br J Cancer       Date:  1999-01       Impact factor: 7.640

3.  Parameters of blood count and tumor markers in patients with borderline ovarian tumors: a retrospective analysis and relation to staging.

Authors:  Rosekeila Simões Nomelini; Taísa Morete da Silva; Beatriz Martins Tavares Murta; Eddie Fernando Candido Murta
Journal:  ISRN Oncol       Date:  2012-04-17

4.  Immunohistochemical profiling of benign, low malignant potential and low grade serous epithelial ovarian tumors.

Authors:  Véronique Ouellet; Tak Hay Ling; Karine Normandin; Jason Madore; Christian Lussier; Véronique Barrès; Dimcho Bachvarov; Claudine Rancourt; Patricia N Tonin; Diane M Provencher; Anne-Marie Mes-Masson
Journal:  BMC Cancer       Date:  2008-11-26       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.